These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 9552377)
21. [Chemical inhibitors of cyclic-dependent kinases: preclinical and clinical study]. Damiens E; Meijer L Pathol Biol (Paris); 2000 Apr; 48(3):340-51. PubMed ID: 10858966 [TBL] [Abstract][Full Text] [Related]
22. The cyclin-dependent kinase inhibitors olomoucine and roscovitine arrest human fibroblasts in G1 phase by specific inhibition of CDK2 kinase activity. Alessi F; Quarta S; Savio M; Riva F; Rossi L; Stivala LA; Scovassi AI; Meijer L; Prosperi E Exp Cell Res; 1998 Nov; 245(1):8-18. PubMed ID: 9828096 [TBL] [Abstract][Full Text] [Related]
23. Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. David-Pfeuty T Oncogene; 1999 Dec; 18(52):7409-22. PubMed ID: 10602500 [TBL] [Abstract][Full Text] [Related]
24. Structure-activity relationship studies of flavopiridol analogues. Murthi KK; Dubay M; McClure C; Brizuela L; Boisclair MD; Worland PJ; Mansuri MM; Pal K Bioorg Med Chem Lett; 2000 May; 10(10):1037-41. PubMed ID: 10843211 [TBL] [Abstract][Full Text] [Related]
25. Association of G1/S-phase and late S-phase checkpoints with regulation of cyclin-dependent kinases in Chinese hamster ovary cells. D'Anna JA; Valdez JG; Habbersett RC; Crissman HA Radiat Res; 1997 Sep; 148(3):260-71. PubMed ID: 9291358 [TBL] [Abstract][Full Text] [Related]
26. Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Gray NS; Wodicka L; Thunnissen AM; Norman TC; Kwon S; Espinoza FH; Morgan DO; Barnes G; LeClerc S; Meijer L; Kim SH; Lockhart DJ; Schultz PG Science; 1998 Jul; 281(5376):533-8. PubMed ID: 9677190 [TBL] [Abstract][Full Text] [Related]
27. The expression of retinoblastoma and Sp1 is increased by low concentrations of cyclin-dependent kinase inhibitors. Peñuelas S; Alemany C; Noé V; Ciudad CJ Eur J Biochem; 2003 Dec; 270(24):4809-22. PubMed ID: 14653808 [TBL] [Abstract][Full Text] [Related]
28. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors. Atienza C; Elliott MJ; Dong YB; Yang HL; Stilwell A; Liu TJ; McMasters KM Int J Mol Med; 2000 Jul; 6(1):55-63. PubMed ID: 10851267 [TBL] [Abstract][Full Text] [Related]
29. CDK inhibitors suppress apoptosis induced by chemicals and by excessive expression of a cell death gene, reaper, in Drosophila cells. Nagano M; Ui-Tei K; Suzuki H; Piao Z; Miyata Y Apoptosis; 2000 Dec; 5(6):543-50. PubMed ID: 11303913 [TBL] [Abstract][Full Text] [Related]
30. Flavopiridol, a cyclin-dependent kinase inhibitor, enhances radiosensitivity of ovarian carcinoma cells. Raju U; Nakata E; Mason KA; Ang KK; Milas L Cancer Res; 2003 Jun; 63(12):3263-7. PubMed ID: 12810657 [TBL] [Abstract][Full Text] [Related]
31. Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects. Kim KS; Sack JS; Tokarski JS; Qian L; Chao ST; Leith L; Kelly YF; Misra RN; Hunt JT; Kimball SD; Humphreys WG; Wautlet BS; Mulheron JG; Webster KR J Med Chem; 2000 Nov; 43(22):4126-34. PubMed ID: 11063609 [TBL] [Abstract][Full Text] [Related]
32. Dual action of the inhibitors of cyclin-dependent kinases: targeting of the cell-cycle progression and activation of wild-type p53 protein. Wesierska-Gadek J; Schmid G Expert Opin Investig Drugs; 2006 Jan; 15(1):23-38. PubMed ID: 16370931 [TBL] [Abstract][Full Text] [Related]
33. Early inhibition of DNA synthesis in the developing rat cerebral cortex by the purine analogues olomoucine and roscovitine. Yakisich JS; Sidén A; Idoyaga Vargas V; Eneroth P; Cruz M Biochem Biophys Res Commun; 1998 Feb; 243(3):674-7. PubMed ID: 9500988 [TBL] [Abstract][Full Text] [Related]
34. Antiproliferative effect of plant cytokinin analogues with an inhibitory activity on cyclin-dependent kinases. Vermeulen K; Strnad M; Krystof V; Havlícek L; Van der Aa A; Lenjou M; Nijs G; Rodrigus I; Stockman B; van Onckelen H; Van Bockstaele DR; Berneman ZN Leukemia; 2002 Mar; 16(3):299-305. PubMed ID: 11896531 [TBL] [Abstract][Full Text] [Related]
35. Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Abraham RT; Acquarone M; Andersen A; Asensi A; Bellé R; Berger F; Bergounioux C; Brunn G; Buquet-Fagot C; Fagot D Biol Cell; 1995; 83(2-3):105-20. PubMed ID: 7549905 [TBL] [Abstract][Full Text] [Related]
36. The design and synthesis of purine inhibitors of CDK2. III. Shum PW; Peet NP; Weintraub PM; Le TB; Zhao Z; Barbone F; Cashman B; Tsay J; Dwyer S; Loos PC; Powers EA; Kropp K; Wright PS; Bitonti A; Dumont J; Borcherding DR Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):1067-78. PubMed ID: 11562960 [TBL] [Abstract][Full Text] [Related]
37. Cyclin-dependent kinase inhibitors block proliferation of human gastric cancer cells. Iseki H; Ko TC; Xue XY; Seapan A; Hellmich MR; Townsend CM Surgery; 1997 Aug; 122(2):187-94; discussion 194-5. PubMed ID: 9288122 [TBL] [Abstract][Full Text] [Related]
40. Cell cycle arrest induced in human breast cancer cells by cyclin-dependent kinase inhibitors: a comparison of the effects exerted by roscovitine and olomoucine. Wesierska-Gadek J; Gueorguieva M; Wojciechowski J; Horky M Pol J Pharmacol; 2004; 56(5):635-41. PubMed ID: 15591654 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]